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Purpose or Objective: The aim of this study was to 
investigate the patterns of failure after radiotherapy for 
pediatric intracranial ependymoma and their correlation to 
dose parameters. 
 
Material and Methods: Between 2000 and 2013, 206 patients 
with intracranial ependymoma were treated in the 13 french 
reference pediatric radiotherapy centers . The magnetic 
resonance imaging obtained at recurrence were registered 
with the original planning CT for topographic analysis of the 
patterns failure. Clinical target volume (CTV) and planning 
target volume (PTV) margins were extracted ; several 
dosimetric quality indices were derived from Dose Volume 
Histogram (DVH) to compare relapse with no-relapse patient. 
 
Results: With a median follow-up of 44.81 months (95% CI 
[36.80; 56.51]), 85 (41.3%) patients presented with 
recurrence. The topographic analysis of patterns of failure 
showed 50 (58.8%) patients with local recurrence in the 
radiation field (LF), 6 (4.1%) in the edge of field (EFG), 6 
(7.1%) were loco-regional outside the field (LRF), 8 (9.4%) in 
spine (SF), 5 supratentorial (SUF) and 10 (11.8%) local and 
distant (LDF). The median prescription dose was respectively: 
55.8 Gy [50.4; 60] in LF, 54 Gy [48.6; 59.4] in EF, 56.7 Gy 
[50.4; 60] in LRF, 54 Gy [50.4; 59.4] in LDF, 59.4 Gy [48.6-
59.4] in SUF and 56.7Gy [54; 60] in SF. The median PTV 
margins was 0.5 mm [0.3; 1]. The median Coverage index and 
The Target Coverage index of the PTV were both lower in the 
relapse group as they were respectively 0.97 and 94.8% in the 
relapse group compared with 0.98 and 95.99% in the no-
relapse group. The median Homogeneity index was 0.097 in 
the relapse group versus 0.091 in the no-relapse group. The 
median volume of relapse was 1.29 cc [0.11; 27] in the LF 
group, with a median dose of 58.81 Gy [50.86; 61.38]. 
 
Conclusion: In patients with intracranial ependymoma, local 
failure in the tumor bed was the major pattern of failure. 
The preliminary results showed that all dosimetric indices on 
the PTV were worse in the relapse group. Improving the 
coverage of target volume may be an effective way to reduce 
the local failures. Thus a complementary correlation of 
relapse patterns with dose parameters to PTV and organs at 
risks and the irradiation techniques is under statistical 
analysis and final results will be presented at the meeting. 
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Purpose or Objective: Since 2009 we launched a strategy for 
children with centrally reviewed MRI diagnosis of diffuse 
intrinsic pontine glioma (DIPG) implying the intravenous 
administration of vinorelbine with nimotuzumab –an anti-
EGFR monoclonal antibody- weekly, for a total of 12 weeks, 
during radiotherapy delivery of 54 Gy, 1.8 Gy/fraction daily. 
After radiotherapy completion, vinorelbine and nimotuzumab 
were administered any other week until tumor progression or 
for a total of two years. In the attempt to improve survival 
and quality of life of our children, a protocol amendment in 
July 2011 introduced re-irradiation at relapse/progression. 
 
Material and Methods: Local re-irradiation consisted of 19.8 
Gy, fractionated over 11 days. A 3DCRT with 5-6 coplanar 
beams was adopted with a beam geometry possibly not 
overlapping that of the first line irradiation; the most 
demanding planning issue of re-irradiation was to meet optic 
chiasm dose constraints. Three additional children were re-
irradiated to distant sites of relapse, spine (2) or ventricular 
system at doses of 36 Gy or 54 Gy respectively. 
Results: Of the 39 patients treated from 8/2009, 28 had local 
(23) or disseminated (5) progression and 18 were given local 
(15) or distant (3) relapse re-irradiation at a median of 8 
months after first radiotherapy (2.5-19 months). Reasons for 
not re-irradiating the other 10 children were: progression 
before July 2011 (4), parents refusal (4), too poor Lansky 
status (2); median PFS and progression site were not 
different in the two subgroups. Survival after re-irradiation 
lasted between two weeks and 14 months, median 6 months, 
and determined a statistically difference in median OS 
between the two groups of re-irradiated or not children, 
being 16 and 12 months, respectively (P=0.004). In 16 
radiologically evaluated patients, re-irradiation induced: 
reduction of tumor volume in 8, stable volume in 3 while 5 
had progression; 13 had symptom amelioration and 12 steroid 
suspension. Volume reductions were obtained in 7/8 children 
that have shown the same response after first line irradiation 
while one was obtained after stable disease in first line 
treatment. No adverse event was reported and all children 
were re-irradiated as outpatients . 
 
Conclusion: Re-irradiation after relapse/progression 
represented a significant benefit for both OS and quality of 
life of children with DIPG with symptom amelioration in 
13/18. This option is worth to be offered also in case of 
disseminated progression.  
Partially supported by Associazione Italiana per la Ricerca sul 
Cancro (AIRC) 
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Purpose or Objective: For the treatment of adult patients 
newly diagnosed with medulloblastoma, there is no standard 
to guide multimodality therapy. With a multi-institutional 
cohort, we investigated and reported the multidisciplinary 
approach, clinical outcome, and prognostic factors of 
medulloblastoma in adult patients treated with postoperative 
radiotherapy (RT). 
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Material and Methods: Thirteen (13) institutions from the 
RCN study group among Europe and United States enrolled 
206 adult medulloblastoma patients who underwent 
postoperative RT between 1976 and 2014. All hospitals 
received their respective Institutional Review Board 
approval, and extracted data were sent to one investigator 
(B.A.) for data analyses. Log-rank univariate and Cox-
modeled multivariate analyses were performed. 
 
Results: There were 118 men and 88 women, and median age 
was 29 (range, 16-67). The median follow-up was 31 months. 
Tumor resection was performed in all patients, and surgery 
was complete in 140 (68%) of the patients. For those patients 
with reported residual volume, 83 (66%) achieved <1.5 cm2 
after resection. Histological subtype was classic (61%) 
predominantly. Postoperative RT was given in 202 (98%) 
patients, and 93% of them received craniospinal irradiation 
(CSI) to a median dose of 36 Gy, with a median RT boost of 
18 Gy to the posterior fossa. Ninety-eight (48%) patients had 
chemotherapy before, after, or concomitant with RT; the 
most common chemotherapy regimens were cisplatin and 
vincristine-based. At 5 and 10 years’ marks, the overall 
survival (OS) rates were 63 and 51%; local control (LC) rates 
were 60 and 46%; and disease-free survival (DFS) rates were 
52 and 38% for all patients, respectively. On univariate 
analyses, Karnofsky performance status (KPS) ≥ 80%, time 
between surgery and RT (≤ 47 days), negative CSF, total RT 
dose ≥ 54 Gy, CSI completion, use of boost field, and 
chemotherapy were associated with better LC, DFS, and OS. 
Additionally, complete surgery, <1.5 cm2 residual volume, 
desmoplastic pathology, and age (≤ 29) were significant 
favorable prognostic factors for DFS and OS. In multivariate 
analyses, KPS ≥ 80% (P<0.001) and CSI (P=0.0002) were the 
remaining significantly favorable prognostic factors for DFS 
and OS; presence of chemotherapy (P=0.0002) and KPS ≥ 80% 
(p=0.03) correlated with better LC rates. 
 
Conclusion: We retrospectively reported the largest clinical 
series for the treatment of adult medulloblastoma and 
elucidated prognostic factors for tumor control and also 
survival outcomes. For patients with high KPS who also 
received CSI, their DFS and OS were better. The use of 
chemotherapy may associate with better local control, 
possibly due to improved radio-sensitization. This information 
should serve as the benchmark and provide the basis for 
future prospective clinical trials in further improving the 
outcome for this group of adult patients with rare 
medulloblastoma. 
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Purpose or Objective: A multicenter randomized trial 
evaluated neurological status (including neurological deaths) 
and cognitive function of patients with resected single brain 
metastasis (BM) after stereotactic radiotherapy of the tumor 
bed (SRT-TB) in comparison with adjuvant whole-brain 
radiotherapy (WBRT). This study reports a preliminary 
comparison of pattern of failure and neurological deaths in 
this trial.  
 
Material and Methods: A planned number of 60 patients was 
randomly assigned into SRT-TB (30) and WBRT (30) arms. 
Inclusion criteria were: total or subtotal resection of BM, 
single BM in the MRI before craniotomy, KPS≥70, life 
expectancy >6 months. Patients in the SRT-TB arm received 
linac-radiosurgery of 15 Gy/1 fraction, or 5 x 5Gy if large 
cavity or proximity of critical structures. WBRT consisted of 
30 Gy in 10 fractions. Evaluation at baseline (before RT), 
eight weeks after RT, and next every three months consisted 
of EORTC QLQ-C30 - BN-20, MiniMental test, KPS, neurologic 
status, and MRI of the brain. Neurological death was defined 
as every death from progression in the brain, toxicity of 
treatment of BM, and from undetermined cause. Crude rates 
of neurological deaths and relapses in the brain were 
compared according to the treatment actually received 
analysis with chi2 test. Overall survival (OS) and interval free 
from neurological death (IFFND) rates were compared with 
log-rank test. 
 
Results: In the SRT-TB arm, six patients were ineligible (new 
BM detected during RT planning [5], withdrawal of consent 
[1]), one received WBRT by error, two had rapid extracranial 
progression (one had no BM treatment, one received WBRT), 
thus finally 21 (72%) patients received the assigned treatment 
in this group. In the WBRT arm, 29 (97%) received the 
assigned treatment. With median follow-up of 12 months 
(range: 1-36) for 26 living patients, one-year OS rates 
(intention-to-treat) were 48% (95% CI: 36-60%) and 61% (95% 
CI: 43-79%) for SRT-TB and WBRT arm, respectively, p=.14. In 
the intention-to-treat analysis, one-year IFFND rates were 
59% (95% CI: 35-84%) and 74% (95% CI: 56-93%) for SRT-TB and 
WBRT arm, respectively, p=.10. In the treatment actually 
received analysis, one-year IFFND rates were 62% (95% CI: 37-
88%) and 72% (95% CI: 53-90%) for SRT-TB and WBRT arm, 
respectively, p=.26. There were 9 (41%) and 9 (30%) 
neurological deaths, in the patients receiving SRT-TB and 
WBRT, respectively, p= .10. 
Ten (45%) of 22 patients treated with SRT-TB had relapse in 
the brain including 5 (23%) relapses in the tumor bed; 9 (31%) 
of 30 patients treated with WBRT had relapse in the brain 
including 7 (24%) relapses in the tumor bed, p=.29. 
 
Conclusion: Our results showed high rate of neurological 
deaths with omission of WBRT, thus such treatment might not 
be safe. Planned analysis of the results from our study that 
will compare neurological and cognitive functions following 
two treatments will be also helpful in decision making 
process. 
 
 
 
